Nautilus Hires VP of Research and Development

Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development 

Connect With ON

GLOBE NEWSWIRE — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development. He and his team will work out of Nautilus’ research headquarters in San Carlos, California.
Dr. Voss brings more than 20 years of experience directing single-molecule biophysics and biochemistry, cell biology, and materials science research at leading biotechnology and life sciences companies. He was previously Vice President of Consumables Research and Development at Pacific Biosciences, where he led scientific efforts to productize the company’s long-read, single-molecule DNA sequencing instruments. Across 13 years, his roles in the development of the company’s Single Molecule, Real-Time (SMRT) Sequencing platform included driving the chemistry underlying SMRT, as well as contributing to instrument and software integration programs.

“With his deep expertise across research and development in single-molecule biochemistry, life sciences platforms, and systems integration, Karl has been instrumental in bringing a foundational long-read, single-molecule sequencing platform from prototype to product,” said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “We are excited to welcome him to our team as we seek to transform our understanding of human biology beyond the genome and drive the type of fundamental advancements in biomedical research that we believe our protein analysis platform can make possible.”

Prior to his work with Pacific Biosciences, Dr. Voss made substantial contributions at Cell Biosciences and Applied Biosystems. Dr. Voss received his B.S. in Biochemistry and Ph.D. in Analytical Chemistry from the University of Alberta.

“Nautilus is taking a truly revolutionary approach to unlocking the potential of proteomics – a relatively untapped but enormously valuable source of information about human biology,” said Dr. Voss. “I’m thrilled to join Nautilus’ stellar leadership team to further develop the first proteomics platform that will power a new era of precision therapies, tools, and applications.”

The appointment of Dr. Voss comes shortly after the debut of Nautilus as a publicly-traded company and the appointments of Emma Lundberg to its Scientific Advisory Board and Matt Murphy as General Counsel. Nautilus completed a business combination with Arya Sciences Acquisition Corp III and received gross proceeds from the transaction totaling approximately $345 million to develop a protein analysis platform with the potential to quantify more than 95% of the proteome. Through innovations in computer science, engineering, and biochemistry, the Nautilus Proteomic Analysis Platform is designed to leverage a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to measure the proteome with extreme sensitivity and scale.

View the full press release published by Nautilus Biotechnology Inc. here.

ON Partners consultant Suzanne Zebedee is proud to have partnered with Nautilus Biotechnology and Karl Voss on this successful placement. View more placements for technology executives here.

About Nautilus Biotechnology, Inc.

Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Follow our work, updates, and recent success on Twitter and LinkedIn.

Find our related successful placements of leading executives here.